Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

A brain cancer patient has been left "confused" and "shattered" after learning he took chemotherapy drugs needlessly for more ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...

[13] After surgery, nine patients had reirradiation and 24 had chemotherapy. The median survival after reoperation was 8, 13, 22 and 47 months for glioblastoma, anaplastic astrocytoma, astrocytoma ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

Jade Collett thought she’d “twinged a nerve” — but she had a terminal tumor pressing on the part of the brain that controls ...

Stephen Blakeston, 53 when he died, began experiencing troubling symptoms in October 2010, including jumbled speech, severe ...

Concomitant radiotherapy plus temozolomide significantly increased progression-free survival versus radiotherapy alone in IDH-wildtype glioblastoma. Treatment with concomitant radiotherapy plus ...

"Good Morning America" co-anchor Michael Strahan and his daughter Isabella Strahan open up about her cancer diagnosis in a ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo ...